Amy Laverdiere

Amy Laverdiere is an accomplished professional in the biotechnology and pharmaceutical sectors with a robust background in product development, strategic planning, and marketing. Currently serving as the Program Lead for MDMA at Lykos Therapeutics, Amy has successfully led the preparation and submission of the NDA for MDMA-assisted therapy for PTSD. Previous roles include leadership positions at Aimmune Therapeutics and Cytokinetics, where responsibilities varied from overseeing the Palforzia Program to directing new product strategy and market analysis for therapies in cardiovascular and neuromuscular diseases. With earlier experience in marketing and process development at Thoratec, Medtronic, and Genentech, Amy has demonstrated a consistent ability to drive product launches and develop innovative marketing strategies. Amy holds a BS in Chemical Engineering from the Massachusetts Institute of Technology and an MBA in Health Sector Management from Duke University.